7:31 PM
 | 
Jun 01, 2009
 |  BC Extra  |  Clinical News

sanofi's BSI-201 meets endpoint

sanofi-aventis Group (Euronext:SAN; NYSE:SNY) said BSI-201 plus gemcitabine and carboplatin met the primary endpoint of clinical benefit rate versus gemcitabine and carboplatin alone in a Phase II trial to treat metastatic triple-negative...

Read the full 147 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >